NCT00600873View on ClinicalTrials.gov

R(+)PPX High Dose Treatment of ALS

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

January 31, 2009

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

R(+) pramipexole dihydrochloride monohydrate

100 mg tid orally daily

Trial Locations (1)

22908

University of Virginia, Charlottesville

All Listed Sponsors
lead

Bennett, James P., Jr., M.D., Ph.D.

INDIV

NCT00600873 - R(+)PPX High Dose Treatment of ALS | Biotech Hunter | Biotech Hunter